Management of Recurrent Low-Grade Stage 1 NMIBC After Mitomycin Failure

Introduction to Treatment Approach

• The National Comprehensive Cancer Network (NCCN) recommends repeat TURBT followed by induction BCG therapy for recurrent low-grade Stage 1 NMIBC after mitomycin failure, as this represents the standard of care for recurrent disease after intravesical chemotherapy failure 1, 2

Immediate Next Step: Repeat TURBT

• Perform another TURBT to completely resect all visible recurrent lesions, as this is essential for accurate restaging and optimal treatment outcomes 1, 2
• The presence of multiple recurrences after initial intravesical chemotherapy indicates treatment failure and necessitates both complete resection and a change in therapeutic approach 1, 3

Post-TURBT Treatment: Switch to BCG Therapy

• The NCCN guidelines explicitly state that patients with recurrent/persistent tumors after initial intravesical treatment can be given a second induction course, but this should be with BCG rather than repeating mitomycin, given the superior efficacy of BCG for T1 disease 1, 2
• BCG is the category 1 recommendation (preferred) for T1 disease, even when low-grade 4, 2

BCG Induction and Maintenance Protocol

• Administer BCG weekly for 6 weeks 1, 3
• Allow a rest period of 4-6 weeks 1
• Perform full reevaluation at week 12 (3 months after starting therapy) with cystoscopy and cytology 1, 2
• Maintenance BCG is strongly recommended if complete response is achieved at 3-month evaluation, though technically optional per guidelines 1, 2
• Maintenance consists of 3 weekly instillations at 3, 6, and 12 months after induction 1
• For high-risk features (multifocal T1 disease), continue maintenance for up to 3 years with instillations at 18, 24, 30, and 36 months 5

Rationale for BCG Over Continued Mitomycin

• The guidelines specify no more than 2 consecutive induction courses of the same agent should be given 1, 2
• BCG with maintenance reduces recurrence risk by 32% compared to mitomycin C in trials with maintenance therapy 1

Addressing Cystectomy Refusal in This Context

• Cystectomy is primarily recommended for high-grade T1 disease that recurs after BCG failure, not after mitomycin failure 4, 1
• The patient deserves a trial of BCG therapy before cystectomy is considered mandatory 1, 2

Surveillance Protocol

• Cystoscopy every 3 months for the first 2 years 1, 2
• If no recurrences, extend to every 6 months in years 3-4 6
• Annual surveillance thereafter 6
• Include urinary cytology at each visit 1, 6

Critical Pitfalls to Avoid

• Do not give immediate post-TURBT chemotherapy in this setting - the patient needs induction BCG, not a single instillation 1, 2
• Do not repeat mitomycin induction - this represents treatment failure requiring a different agent 1, 2
• Do not skip maintenance BCG - this is where much of the benefit comes from, particularly for preventing progression 1, 2, 5

When to Reconsider Cystectomy

• The patient should be counseled that cystectomy becomes the primary recommendation if high-grade disease appears on subsequent biopsies 4, 1
• Disease persists or recurs after adequate BCG therapy (BCG-unresponsive disease) 1, 5
• Progression to muscle-invasive disease occurs 4, 5